NIR Diagnostics And LifeScan, Inc. Extend First Option Agreement

CAMPBELLVILLE, ON, Oct. 12 /CNW/ - NIR Diagnostics Inc. (TSX Venture: NID), a leading-edge developer of handheld spectroscopy based medical instruments, today announced that it has reached an agreement with Lifescan, Inc., a leading maker of blood glucose monitoring systems, to extend by six months the feasibility study and first option agreement previously announced on January 3, 2006. The first option will now expire March 31, 2007 rather than September 30, 2006.

Back to news